All PlansReimbursementMedium impact
Newsletter Vol. 8, No. 31
New Jersey Medicaid·NJ · Oncology, Hematology, Rheumatology·Provider Notice
We identified it
Jun 20, 2026
Summary
This policy change provides reimbursement updates for Rituxan (Rituximab), a specialty medication used primarily in oncology and rheumatology treatments. Billing teams should review current billing procedures for Rituximab administration to ensure compliance with new reimbursement guidelines.
Action Required
Immediately: Billing team should download and review the complete policy document from https://www.njmmis.com/documentDownload.aspx?document=8-31.pdf to understand specific reimbursement changes for Rituxan (Rituximab). Update billing procedures and fee schedules as specified in the full policy. Notify providers administering Rituximab of any documentation or coding changes required.